All News
ACR 2025 – Day 2 Report
Here are 3 abstracts that caught my eye on Day 2 at ACR25. Notably these have takeaway messages that should support your current practices.
Read Article
ACR25 Best Abstracts - Day 2
After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2.
Read Article
Are we putting the CAR-T before the horse?
CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure.
Read Article
PMR patients need healthcare professionals who know a bit about their disease.
Survey of US HCPs, amongst responders:
- 68% were not aware/unsure about PMR
- of those who were aware, knowledge was… not great (see below)
PMR needs everyone’s respect
#ACR25 ABST1617 @RheumNow https://t.co/SpyEnAW8lI
David Liew drdavidliew ( View Tweet)
“The true master clinicians I know have an exceptional tolerance for uncertainty”
- @LCalabreseDO, #ACR25
(Gary Hoffman and Carol Langford got a specific name check there too)
‘Fake Rheum: Case-Based Approach to Rheumatology Mimics” @CCalabreseDO @RheumNow https://t.co/VkKXoMn1Ls
David Liew drdavidliew ( View Tweet)
The first father-daughter session at ACR?
Brilliant session in diagnostic thinking and mimics in rheumatology from @LCalabreseDO and @CCalabreseDO, teasing apart heuristics, biases, and examples straddling the ID-Rheum divide. Well worth catching on the replay #ACR25 @RheumNow https://t.co/16FEqVyDGg
Links:
David Liew drdavidliew ( View Tweet)
In a Brazilian cohort (n=791), axSpA diagnosis delay dropped from 41.7 yrs (1960s) to 1.9 yrs (2020s). Female representation rose to 50%. Non-radiographic axSpA now 16.7%. MRI and updated criteria driving earlier, more equitable recognition. Abstract#1407 @RheumNow #ACR25 https://t.co/8hIpX0a1Sa
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
How many patients do you need to treat to prevent one RA conversion in at-risk individuals?
APPIPRA and ALTO Interception studies, long term data
Number Necessary to Treat to prevent 1 RA conversion across time:
1yr = 4
2yrs = 7
3, 4, 5 yrs = 9
6 yrs = 11
#ACR25 #ABSTRACT1678 https://t.co/GBzUJG8jVk
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Abstr#1401 Sjogren’s #SjD is definitely not a benign disease! Real world study using US database showed high disease burden within 12 mths of diagnosis (i.e. healthcare resource use). GC use was high (~50%). Better therapy is needed to improve outcomes @RheumNow https://t.co/MI3vQ5LByr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACRBest @RheumNow https://t.co/K8kmlzIjxt
Aurelie Najm AurelieRheumo ( View Tweet)
At the Global Rheum Summit, patients called for care that values people, not just disease.
✅ Respect lived experience
✅ Enable shared decisions
✅ Support education & coordination of care decisions.
@RheumNow #ACR25
Jiha Lee JihaRheum ( View Tweet)
#ACR25 Please find our Day 1 Recap of the conference where we discussed our favourite abstracts and learning points 😃 @Janetbirdope @AurelieRheumo @RheumNow https://t.co/X125tjyqi5
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Did we need a 2nd Interception RCT of HCQ in Pre-RA?
Unsure but in any case, it does not work either
STOPRA CCP3+>=2 ind 71 HCQ and 74 PBO
36 months RA conversion
Dr Deane's take: "probably wrong drug rather than wrong timing"
#ACR25 @RheumNow #ABSTRACT1674 https://t.co/jysdo8iz7v
Aurelie Najm AurelieRheumo ( View Tweet)
Like PEXIVAS steroid taper, this is something we need an online resource to check each time. Its complicated, but feels "right". @RheumNow #ACR25 https://t.co/QAgSQB9XMQ
Richard Conway RichardPAConway ( View Tweet)
Global survey from the 2024 Adelphi Lupus Dse Specific Programme evaluated pt burden & MD/Pt Tx preferences:
Efficacy & safety - top 2 MD-reported reasons for tx initiation
OD, oral dosing-most preferred mode by MD & Pts
Shared decision-making is key
#ACR25 @RheumNow Abs1551 https://t.co/rmpCATCa78
sheila RHEUMarampa ( View Tweet)
Screening for ILD in RA patients:
CXR and PFTs by themselves are close to a waste of time.
When it comes to screening (high-risk) RA patients, it’s HRCT (or lung USS) or nothing really.
(in keeping with EULAR, ACR guidelines)
#ACR25 ABST1335 @RheumNow https://t.co/XBDxLwYsAT
David Liew drdavidliew ( View Tweet)
This poster is absolutely bonkers & I LOVE it
Huge table. Frequency of everything over time
Really interesting to see which activity persists / how much damage is accumulated
Every trial should be obligated to share this (esp SLE!)
#ACR25 @RheumNow #ACRBest Abst#1608 https://t.co/blRrvwi3qP
Mike Putman EBRheum ( View Tweet)
Getting RA patients into remission: have we plateaued?
@MayoClinic data: early and later into the biologic era, and still median time to RA remission is >3y
Surely we can aspire to more? Let’s target barriers to implementing better
#ACR25 @ElHasbaniG @MyasoedovaElena @RheumNow https://t.co/JLTuL5cIet
David Liew drdavidliew ( View Tweet)
